Computer-Aided Segmentation and Volumetry of Artificial Ground-Glass Nodules at Chest CT

2013 ◽  
Vol 201 (2) ◽  
pp. 295-300 ◽  
Author(s):  
Ernst Th. Scholten ◽  
Colin Jacobs ◽  
Bram van Ginneken ◽  
Martin J. Willemink ◽  
Jan-Martin Kuhnigk ◽  
...  
2018 ◽  
Vol 24 (5) ◽  
pp. 31-39
Author(s):  
So Hyun Byun ◽  
홍헬렌 ◽  
김형진 ◽  
박창민 ◽  
정주립 ◽  
...  

2008 ◽  
Vol 19 (3) ◽  
pp. 552-560 ◽  
Author(s):  
Hyun Ju Lee ◽  
Jin Mo Goo ◽  
Chang Hyun Lee ◽  
Chang Min Park ◽  
Kwang Gi Kim ◽  
...  

2011 ◽  
Vol 196 (3) ◽  
pp. 533-543 ◽  
Author(s):  
Jin Mo Goo ◽  
Chang Min Park ◽  
Hyun Ju Lee

Author(s):  
Ali H. Elmokadem ◽  
Dalia Bayoumi ◽  
Sherif A. Abo-Hedibah ◽  
Ahmed El-Morsy

Abstract Background To evaluate the diagnostic performance of chest CT in differentiating coronavirus disease 2019 (COVID-19) and non-COVID-19 causes of ground-glass opacities (GGO). Results A total of 80 patients (49 males and 31 females, 46.48 ± 16.09 years) confirmed with COVID-19 by RT-PCR and who underwent chest CT scan within 2 weeks of symptoms, and 100 patients (55 males and 45 females, 48.94 ± 18.97 years) presented with GGO on chest CT were enrolled in the study. Three radiologists reviewed all CT chest exams after removal of all identifying data from the images. They expressed the result as positive or negative for COVID-19 and recorded the other pulmonary CT features with mention of laterality, lobar affection, and distribution pattern. The clinical data and laboratory findings were recorded. Chest CT offered diagnostic accuracy ranging from 59 to 77.2% in differentiating COVID-19- from non-COVID-19-associated GGO with sensitivity from 76.25 to 90% and specificity from 45 to 67%. The specificity was lower when differentiating COVID-19 from non-COVID-19 viral pneumonias (30.5–61.1%) and higher (53.1–70.3%) after exclusion of viral pneumonia from the non-COVID-19 group. Patients with COVID-19 were more likely to have lesions in lower lobes (p = 0.005), peripheral distribution (p < 0.001), isolated ground-glass opacity (p = 0.043), subpleural bands (p = 0.048), reverse halo sign (p = 0.005), and vascular thickening (p = 0.013) but less likely to have pulmonary nodules (p < 0.001), traction bronchiectasis (p = 0.005), pleural effusion (p < 0.001), and lymphadenopathy (p < 0.001). Conclusions Chest CT offered reasonable sensitivity when differentiating COVID-19- from non-COVID-19-associated GGO with low specificity when differentiating COVID-19 from other viral pneumonias and moderate specificity when differentiating COVID-19 from other causes of GGO.


2020 ◽  
Vol 215 (2) ◽  
pp. 351-358 ◽  
Author(s):  
Zhi-gang Chu ◽  
Wang-jia Li ◽  
Bin-jie Fu ◽  
Fa-jin Lv

2021 ◽  
pp. 34-38
Author(s):  
Satoshi Muto ◽  
Yuki Ozaki ◽  
Takuya Inoue ◽  
Naoyuki Okabe ◽  
Yuki Matsumura ◽  
...  

Although diffuse cysts in the lung can be found in many diseases, they are uncommon in metastatic lung adenocarcinoma. They are even more unusual after the administration of immune checkpoint inhibitors. A case of lung adenocarcinoma that developed diffuse cysts in the lungs during treatment with nivolumab is reported. The patient was a 60-year-old woman with postoperative recurrent lung adenocarcinoma in mediastinal lymph nodes and pleural dissemination. After first-line treatment with cisplatin, pemetrexed, and bevacizumab, computed tomography (CT) showed disease progression. Treatment was then switched to nivolumab. After 5 courses of nivolumab, CT showed multiple ground-glass nodules in her lungs. After 4 more courses of nivolumab, the ground-glass nodules increased in size, and cystic air spaces appeared in their centers. The patient did not have any symptoms. Laboratory tests showed no evidence of infection or nivolumab-induced pneumonitis. Sialyl Lewis X-i antigen increased, and positron emission tomography showed abnormal uptake of 18F-fluorodeoxyglucose in these lesions. Considering this evidence, the cystic lesions were diagnosed as multiple lung metastases. Various differential diagnoses should be considered when diffuse cystic lesions are found in the lungs after the administration of immune checkpoint inhibitors.


2015 ◽  
Vol 29 (7) ◽  
pp. 890-895
Author(s):  
Naoya Yokomakura ◽  
Hiroo Nishijima ◽  
Masakazu Yanagi ◽  
Kazuhiro Wakida ◽  
Aya Harada ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document